A Single-center, Single-arm, Phase II Clinical Study of Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary) ; Surufatinib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
Most Recent Events
- 20 Jan 2024 Preliminary results (N=15) assessing the efficacy and safety of surufatinib plus sintilimab (an anti-PD-1 antibody),nab-paclitaxel and gemcitabine(AG) as first-line therapy for mPDAC patients, presented at the 2024 Gastrointestinal Cancers Symposium
- 08 Aug 2023 Status changed from not yet recruiting to recruiting.
- 05 Aug 2022 New trial record